CA2229405C - Methods for enhancing the production of interferon in cell culture - Google Patents

Methods for enhancing the production of interferon in cell culture Download PDF

Info

Publication number: CA2229405C
Authority: CA; Canada
Prior art keywords: cell; interferon; pkr; poly; progeny
Prior art date: 1995-08-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002229405A

Other languages

English (en)

French (fr)

Other versions

CA2229405A1 (en

Inventor

Allan S. Lau

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California San Diego UCSD

Original Assignee

University of California San Diego UCSD

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-22

Filing date

1996-08-22

Publication date

2004-03-02

1996-08-22 Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD

1997-03-06 Publication of CA2229405A1 publication Critical patent/CA2229405A1/en

2004-03-02 Application granted granted Critical

2004-03-02 Publication of CA2229405C publication Critical patent/CA2229405C/en

2016-08-22 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

108010050904 Interferons Proteins 0.000 title claims abstract description 98
102000014150 Interferons Human genes 0.000 title claims abstract description 94
229940079322 interferon Drugs 0.000 title claims abstract description 70
238000000034 method Methods 0.000 title claims abstract description 42
238000004519 manufacturing process Methods 0.000 title claims abstract description 27
238000004113 cell culture Methods 0.000 title abstract description 27
230000002708 enhancing effect Effects 0.000 title abstract description 8
239000000411 inducer Substances 0.000 claims abstract description 40
229940047124 interferons Drugs 0.000 claims abstract description 23
230000016396 cytokine production Effects 0.000 claims abstract description 13
210000004027 cell Anatomy 0.000 claims description 124
108010037623 eIF-2 Kinase Proteins 0.000 claims description 74
102000010982 eIF-2 Kinase Human genes 0.000 claims description 64
230000014509 gene expression Effects 0.000 claims description 17
230000037452 priming Effects 0.000 claims description 17
230000001939 inductive effect Effects 0.000 claims description 14
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical group C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 12
230000003612 virological effect Effects 0.000 claims description 11
230000001965 increasing effect Effects 0.000 claims description 9
210000002950 fibroblast Anatomy 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 7
241000711404 Avian avulavirus 1 Species 0.000 claims description 6
241000606161 Chlamydia Species 0.000 claims description 6
241000711408 Murine respirovirus Species 0.000 claims description 6
241000606701 Rickettsia Species 0.000 claims description 6
210000003719 b-lymphocyte Anatomy 0.000 claims description 6
239000003226 mitogen Substances 0.000 claims description 6
210000001616 monocyte Anatomy 0.000 claims description 6
102000003792 Metallothionein Human genes 0.000 claims description 4
108090000157 Metallothionein Proteins 0.000 claims description 4
238000012258 culturing Methods 0.000 claims description 3
210000005260 human cell Anatomy 0.000 claims description 3
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 2
239000003710 calcium ionophore Substances 0.000 claims description 2
239000003862 glucocorticoid Substances 0.000 claims description 2
230000035939 shock Effects 0.000 claims description 2
230000006698 induction Effects 0.000 abstract description 19
241000700605 Viruses Species 0.000 abstract description 15
210000004102 animal cell Anatomy 0.000 abstract description 11
108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 10
102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 8
108091000080 Phosphotransferase Proteins 0.000 abstract description 5
102000020233 phosphotransferase Human genes 0.000 abstract description 5
230000015572 biosynthetic process Effects 0.000 abstract description 3
230000001413 cellular effect Effects 0.000 abstract description 3
230000001419 dependent effect Effects 0.000 abstract description 3
238000003786 synthesis reaction Methods 0.000 abstract description 2
108090000623 proteins and genes Proteins 0.000 description 14
238000012261 overproduction Methods 0.000 description 11
241000701022 Cytomegalovirus Species 0.000 description 9
241000710188 Encephalomyocarditis virus Species 0.000 description 8
230000000694 effects Effects 0.000 description 8
241001529936 Murinae Species 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
230000035897 transcription Effects 0.000 description 5
238000013518 transcription Methods 0.000 description 5
238000011282 treatment Methods 0.000 description 5
102000003960 Ligases Human genes 0.000 description 4
108090000364 Ligases Proteins 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
229920000936 Agarose Polymers 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000002799 interferon inducing agent Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000004044 response Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
208000035473 Communicable disease Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000008014 Eukaryotic Initiation Factor-2 Human genes 0.000 description 2
108010089791 Eukaryotic Initiation Factor-2 Proteins 0.000 description 2
101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 2
108700002232 Immediate-Early Genes Proteins 0.000 description 2
102000001617 Interferon Receptors Human genes 0.000 description 2
108010054267 Interferon Receptors Proteins 0.000 description 2
108010014726 Interferon Type I Proteins 0.000 description 2
102000002227 Interferon Type I Human genes 0.000 description 2
102100036981 Interferon regulatory factor 1 Human genes 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
108010006025 bovine growth hormone Proteins 0.000 description 2
YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
210000004544 dc2 Anatomy 0.000 description 2
230000034994 death Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
102000044003 human EIF2AK2 Human genes 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
239000000047 product Substances 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
210000001995 reticulocyte Anatomy 0.000 description 2
108091008023 transcriptional regulators Proteins 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
101150090724 3 gene Proteins 0.000 description 1
108090000656 Annexin A6 Proteins 0.000 description 1
102100034278 Annexin A6 Human genes 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
208000000907 Condylomata Acuminata Diseases 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
101150091206 Nfkbia gene Proteins 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
201000004201 anogenital venereal wart Diseases 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000005860 defense response to virus Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000010502 episomal replication Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000036737 immune function Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000004064 recycling Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000007727 signaling mechanism Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000002594 sorbent Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
150000003682 vanadium compounds Chemical class 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000006656 viral protein synthesis Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32051—Methods of production or purification of viral material

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Virology (AREA)
Plant Pathology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Analytical Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

CA002229405A 1995-08-22 1996-08-22 Methods for enhancing the production of interferon in cell culture Expired - Fee Related CA2229405C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US262195P	1995-08-22	1995-08-22
US60/002,621		1995-08-22
PCT/US1996/013627 WO1997008324A1 (en)	1995-08-22	1996-08-22	Methods for enhancing the production of interferon in cell culture

Publications (2)

Publication Number	Publication Date
CA2229405A1 CA2229405A1 (en)	1997-03-06
CA2229405C true CA2229405C (en)	2004-03-02

Family

ID=21701659

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA002229405A Expired - Fee Related CA2229405C (en)	1995-08-22	1996-08-22	Methods for enhancing the production of interferon in cell culture
CA2229163A Expired - Lifetime CA2229163C (en)	1995-08-22	1996-08-22	Methods for enhancing the production of viral vaccines in cell culture by interferon suppression

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CA2229163A Expired - Lifetime CA2229163C (en)	1995-08-22	1996-08-22	Methods for enhancing the production of viral vaccines in cell culture by interferon suppression

Country Status (10)

Country	Link
US (6)	US5840565A (2)
EP (2)	EP0846174A4 (2)
JP (2)	JP3432519B2 (2)
CN (1)	CN1161469C (2)
AT (1)	ATE289348T1 (2)
AU (2)	AU707130B2 (2)
BR (1)	BR9610550A (2)
CA (2)	CA2229405C (2)
DE (1)	DE69634360T2 (2)
WO (2)	WO1997008324A1 (2)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6855519B2 (en) *	1995-08-22	2005-02-15	The Regents Of The University Of California	Methods for enhancing the production of interferon in cell culture
US5840565A (en) *	1995-08-22	1998-11-24	The Regents Of The University Of California	Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6740519B1 (en)	1997-11-03	2004-05-25	Mount Sinai School Of Medicine	Immortalized, homozygous stat1-deficient mammalian cell lines and their uses
KR100637937B1 (ko) *	1998-06-12	2006-10-23	마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티	변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스
US6762038B1 (en)	1998-09-09	2004-07-13	The Cleveland Clinic Foundation	Mutant cell lines and methods for producing enhanced levels of recombinant proteins
CA2376487A1 (en) *	1999-06-15	2000-12-21	Allan S. Lau	Methods for enhancing the production of cytokines in cell culture
EP1067179A1 (en) *	1999-07-09	2001-01-10	Pierre Fabre Medicament	Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
AU7126000A (en) *	1999-09-08	2001-04-10	Genetrol Biotherapeutics, Inc.	High level cytokine production with enhanced cell viability
US20010031859A1 (en) *	1999-09-08	2001-10-18	Lau Allan S.	High level cytokine production with enhanced cell viability
WO2001077394A1 (en)	2000-04-10	2001-10-18	Mount Sinai School Of Medicine Of New York University	Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
IL136232A0 (en) *	2000-05-18	2001-05-20	Bar Ilan University Res Author	Measurements of enzymatic activity in a single, individual cell in population
US6660471B2 (en) *	2000-08-04	2003-12-09	Chiron Corporation	Enhanced replication of HCV RNA
US20020150541A1 (en) *	2000-09-12	2002-10-17	Gene Trol Biotherapeutics, Inc.	Compositions comprising mixtures of therapeutic proteins and methods of producing the same
AU2001290855A1 (en)	2000-09-14	2002-03-26	Genetrol Biotherapeutics, Inc.	Method and cell composition for screening compounds for anti-inflammatory activity
US20020115212A1 (en) *	2000-12-19	2002-08-22	Browning Laura A.	Enchanced PKR expression and cytokine production
DE10104094C1 (de) *	2001-01-31	2002-07-25	Angelika Vallbracht-Flehmig	Verfahren zur Erhöhung der Virusvermehrung und Virusausbeute in Zellkulturen, durch Blockade der RNaseL-Aktivierung
WO2003035824A1 (en) *	2001-10-25	2003-05-01	Bar-Ilan University	Interactive transparent individual cells biochip processor
IL154677A0 (en)	2003-02-27	2003-09-17	Univ Bar Ilan	A method and apparatus for manipulating an individual cell
EP1654347B1 (en) *	2003-06-26	2014-06-04	Seng Enterprises Limited	Improved materials for constructing cell-chips, cell-chip covers, cell-chip coats, processed cell-chips and uses thereof
US8597597B2 (en)	2003-06-26	2013-12-03	Seng Enterprises Ltd.	Picoliter well holding device and method of making the same
US9200245B2 (en)	2003-06-26	2015-12-01	Seng Enterprises Ltd.	Multiwell plate
US7888110B2 (en)	2003-06-26	2011-02-15	Seng Enterprises Ltd.	Pico liter well holding device and method of making the same
WO2005008626A1 (en) *	2003-07-11	2005-01-27	University Of North Carolina At Chapel Hill	Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) *	2003-08-11	2005-03-24	Mordechai Deutsch	Population of cells utilizable for substance detection and methods and devices using same
RU2390351C2 (ru) *	2003-08-11	2010-05-27	Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити	Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
JP2007529199A (ja) *	2003-10-23	2007-10-25	イルミジェンバイオサイエンシーズ，インコーポレイテッド	ウイルス感染に対する抵抗性に関連する遺伝子である、ｏａｓ１における変異の検出
US20050191649A1 (en) *	2003-10-23	2005-09-01	Illumigen Biosciences, Inc.	Detection of mutations in a gene associated with resistance to viral infection, OAS1
EP2327724A3 (en)	2004-02-02	2011-07-27	Ambrx, Inc.	Modified human growth hormone polypeptides and their uses
BRPI0506610A (pt) *	2004-02-03	2007-05-02	Chemagis Ltd	montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
NZ548495A (en) *	2004-02-23	2009-05-31	Crucell Holland Bv	Virus purification methods
EP3332803B1 (en)	2004-06-01	2021-09-08	Icahn School of Medicine at Mount Sinai	Genetically engineered swine influenza virus and uses thereof
EP1763665A1 (en) *	2004-07-07	2007-03-21	Seng Enterprises Limited	Method and device for identifying an image of a well in an image of a well-bearing component
US7403647B2 (en) *	2004-09-13	2008-07-22	Seng Enterprises Ltd.	Method for identifying an image of a well in an image of a well-bearing component
WO2006021959A2 (en) *	2004-08-25	2006-03-02	Seng Enterprises Ltd.	Method and device for isolating cells
US20060051369A1 (en) *	2004-08-27	2006-03-09	Taylor Deborah R	ADAR1 antiviral pathway
US20080107683A1 (en) *	2004-11-30	2008-05-08	David Hone	Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof
EP1866075B1 (en)	2005-01-25	2010-09-08	Seng Enterprises Limited	Microfluidic device for studying cells
WO2006088481A2 (en)	2005-02-15	2006-08-24	Mount Sinai School Of Medicine Of New York University	Genetically engineered equine influenza virus and uses thereof
DK1869171T4 (en) *	2005-04-11	2016-01-18	Crucell Holland Bv	Virus cleaning using ultrafiltration
UA95446C2 (ru) *	2005-05-04	2011-08-10	Іллюміджен Байосайєнсіз, Інк.	Мутаци в генах oas1
DE102005034043B4 (de) *	2005-07-18	2019-12-12	Südzucker Aktiengesellschaft Mannheim/Ochsenfurt	Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch
US20070111309A1 (en) *	2005-10-04	2007-05-17	Daelli Marcelo G	Vero cell line adapted to grow in suspension
US20070141555A1 (en) *	2005-10-11	2007-06-21	Mordechai Deutsch	Current damper for the study of cells
WO2007052245A1 (en)	2005-11-03	2007-05-10	Seng Enterprises Ltd.	Method and device for studying floating, living cells
US20070196333A1 (en) *	2006-02-23	2007-08-23	Fu-Yung Lin	Composition comprising mixtures of IFN-alpha subtypes
US20060223999A1 (en) *	2006-05-10	2006-10-05	Chemagis Ltd.	Process for preparing montelukast and precursors thereof
MX2009011870A (es)	2007-05-02	2009-11-12	Ambrx Inc	Polipeptidos de interferon beta modificados y usos de los mismos.
US9145540B1 (en)	2007-11-15	2015-09-29	Seng Enterprises Ltd.	Device for the study of living cells
EP2237887A2 (en)	2007-12-26	2010-10-13	Seng Enterprises Ltd.	Device for the study of living cells
NZ586947A (en)	2008-02-08	2012-11-30	Ambrx Inc	Modified leptin polypeptides and their uses
EP2133358A1 (en) *	2008-06-10	2009-12-16	Universitätsklinikum Freiburg	Rift valley fever virus-like particles and their use for immunization and as test system
MY172788A (en)	2008-08-01	2019-12-12	Gamma Vaccines Pty Ltd	Influenza vaccines
JP5686741B2 (ja)	2008-12-16	2015-03-18	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	インフルエンザワクチンの生成
US9644187B2 (en)	2010-04-14	2017-05-09	Emd Millipore Corporation	Methods of producing high titer, high purity virus stocks and methods of use thereof
US20140079732A1 (en)	2011-01-27	2014-03-20	Gamma Vaccines Pty Limited	Combination vaccines
WO2013182498A1 (en) *	2012-06-04	2013-12-12	Novartis Ag	Improved safety testing
KR20150133695A (ko) *	2013-02-05	2015-11-30	유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드	바이러스 제조를 위한 세포주 및 이의 사용 방법
JP6722686B2 (ja)	2015-02-26	2020-07-15	ベーリンガーインゲルハイムフェトメディカゲーエムベーハーＢｏｅｈｒｉｎｇｅｒＩｎｇｅｌｈｅｉｍＶｅｔｍｅｄｉｃａＧｍｂＨ	二価ブタインフルエンザウイルスワクチン
WO2017070167A1 (en) *	2015-10-20	2017-04-27	The University Of North Carolina At Chapel Hill	Methods and compositions for modified factor ix fusion proteins
KR102651055B1 (ko)	2016-03-24	2024-03-26	삼성디스플레이 주식회사	광학 필름 및 디스플레이 장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE33164E (en) *	1979-05-15	1990-02-13	Mobay Corporation	Influenza vaccine production in liquid cell culture
JPS5754586A (en) *	1980-09-18	1982-04-01	Ajinomoto Co Inc	Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it
US4579821A (en) *	1981-11-23	1986-04-01	University Patents, Inc.	Control of DNA sequence transcription
JPS58209993A (ja) *	1982-05-31	1983-12-07	Mochida Pharmaceut Co Ltd	インタ−フエロンの産生方法
CA1211397A (en) *	1982-06-21	1986-09-16	Michael D. Johnston	Production of antiviral agents
US4485038A (en) *	1982-10-19	1984-11-27	Health Research (Roswell Park Division)	Method for the production and purification of human leukocyte interferon
US4966843A (en) *	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
US4745053A (en) *	1983-07-08	1988-05-17	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyojo	Process for producing human interferon and method for assaying the interferon productivity of blood
JPS6062997A (ja) *	1983-09-17	1985-04-11	Mochida Pharmaceut Co Ltd	インタ−フエロンの生産方法
US5196323A (en) *	1985-04-27	1993-03-23	Boehringer Ingelheim International Gmbh	Process for preparing and purifying alpha-interferon
US4732683A (en) *	1986-12-02	1988-03-22	Biospectrum, Inc.	Purification method for alpha interferon
EP0414475B1 (en) *	1989-08-25	1997-12-10	Chiron Corporation	Methods for culturing HCV in B- or T-lymphocyte cell lines
US5149531A (en) *	1990-06-27	1992-09-22	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
JPH05260981A (ja) *	1992-03-02	1993-10-12	Massachusetts Inst Of Technol <Mit>	ヘムに調節される真核細胞開始因子２αキナーゼをコードするＤＮＡ
FR2689520B1 (fr) *	1992-04-03	1996-07-19	Bio Merieux	Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
US5840565A (en)	1995-08-22	1998-11-24	The Regents Of The University Of California	Methods for enhancing the production of viral vaccines in PKR-deficient cell culture

1996
- 1996-08-21 US US08/700,198 patent/US5840565A/en not_active Expired - Lifetime
- 1996-08-22 AU AU68608/96A patent/AU707130B2/en not_active Expired
- 1996-08-22 CN CNB961977515A patent/CN1161469C/zh not_active Expired - Fee Related
- 1996-08-22 WO PCT/US1996/013627 patent/WO1997008324A1/en not_active Ceased
- 1996-08-22 AU AU68576/96A patent/AU6857696A/en not_active Abandoned
- 1996-08-22 EP EP96929017A patent/EP0846174A4/en not_active Withdrawn
- 1996-08-22 EP EP96929066A patent/EP0846160B1/en not_active Expired - Lifetime
- 1996-08-22 WO PCT/US1996/013745 patent/WO1997008292A1/en not_active Ceased
- 1996-08-22 BR BR9610550A patent/BR9610550A/pt not_active Application Discontinuation
- 1996-08-22 AT AT96929066T patent/ATE289348T1/de active
- 1996-08-22 JP JP51045097A patent/JP3432519B2/ja not_active Expired - Fee Related
- 1996-08-22 CA CA002229405A patent/CA2229405C/en not_active Expired - Fee Related
- 1996-08-22 DE DE69634360T patent/DE69634360T2/de not_active Expired - Lifetime
- 1996-08-22 CA CA2229163A patent/CA2229163C/en not_active Expired - Lifetime
- 1996-08-22 JP JP51050897A patent/JP4267693B2/ja not_active Expired - Lifetime
1999
- 1999-11-19 US US09/444,224 patent/US6159712A/en not_active Expired - Fee Related
2000
- 2000-06-12 US US09/591,813 patent/US6489144B1/en not_active Expired - Fee Related
- 2000-12-13 US US09/737,126 patent/US6686190B2/en not_active Expired - Lifetime
- 2000-12-13 US US09/736,748 patent/US6673591B2/en not_active Expired - Fee Related
2003
- 2003-11-24 US US10/722,349 patent/US7132271B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0846160B1 (en)	2005-02-16
AU6860896A (en)	1997-03-19
JP4267693B2 (ja)	2009-05-27
US6489144B1 (en)	2002-12-03
JP3432519B2 (ja)	2003-08-04
AU6857696A (en)	1997-03-19
US6686190B2 (en)	2004-02-03
BR9610550A (pt)	1999-07-06
CA2229163A1 (en)	1997-03-06
CN1200148A (zh)	1998-11-25
US20040157310A1 (en)	2004-08-12
US20010001709A1 (en)	2001-05-24
US20010001290A1 (en)	2001-05-17
AU707130B2 (en)	1999-07-01
EP0846160A1 (en)	1998-06-10
JPH11511324A (ja)	1999-10-05
ATE289348T1 (de)	2005-03-15
EP0846160A4 (en)	2002-01-02
US5840565A (en)	1998-11-24
CN1161469C (zh)	2004-08-11
EP0846174A4 (en)	2003-02-05
EP0846174A1 (en)	1998-06-10
US7132271B2 (en)	2006-11-07
WO1997008292A1 (en)	1997-03-06
CA2229405A1 (en)	1997-03-06
DE69634360T2 (de)	2005-12-29
US6159712A (en)	2000-12-12
JPH11514344A (ja)	1999-12-07
DE69634360D1 (de)	2005-03-24
US6673591B2 (en)	2004-01-06
CA2229163C (en)	2011-04-05
WO1997008324A1 (en)	1997-03-06
MX9801423A (es)	1998-05-31

Legal Events

Date	Code	Title	Description
2001-06-21	EEER	Examination request
2008-08-22	MKLA	Lapsed

Publication	Publication Date	Title
CA2229405C (en)	2004-03-02	Methods for enhancing the production of interferon in cell culture
US4727138A (en)	1988-02-23	Human immune interferon
JP3260368B2 (ja)	2002-02-25	インターロイキン−１０による腫瘍性疾患の処置
US5582824A (en)	1996-12-10	Recombinant DES-CYS-TYR-CYS human immune interferon
JP2003509012A (ja)	2003-03-11	細胞培養物中でのサイトカインの産生を増強するための方法
US6864061B2 (en)	2005-03-08	Method for screening compounds for anti-inflammatory activity
EP1214399B1 (en)	2007-07-11	High level cytokine production with enhanced cell viability
US6855519B2 (en)	2005-02-15	Methods for enhancing the production of interferon in cell culture
US5686263A (en)	1997-11-11	Method for enhancing gene expression
Otsuka et al.	1982	Inhibition by interferon of biochemical transformation induced by cloned herpesvirus thymidine kinase genes
MXPA98001423A (en)	1998-10-23	Methods to improve the production of viral vaccines in cellular cultivation through interruption suppression
Mosmann	1992	Section II: In Vitro Effects of IL-4 121
JPH0832236B2 (ja)	1996-03-29	組換えヒトインターロイキン２およびその製造法